GB2597309A — Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities

USPTO Abstract

A cannabidiol (CBD) preparation for use in the treatment of seizures associated with gross chromosomal mutation. The gross chromosomal mutation can be 15q11.2 deletion, 1p36 deletion, 22Q11 duplication, 9p21.1 deletion with autistic spectrum disorder, monosomy 16p13.3 and trisomy 2p25.3, chromosome 3q duplication, or trisomy 13. The seizures can be tonic, tonic-clonic, atonic, absence, focal seizures without impairment, and focal seizures with secondary generalisation. The CBD preparation can comprise greater than 95% (w/w) CBD and not more than 0.15% (w/w) tetrahydrocannabinol (THC). The CBD preparation can comprise less than or equal to 2% (w/w) other cannabinoids comprising THC, cannabidiol C-1 (CBD-C1), cannabidivarin (CBDV), or cannabidiol C-4 (CBD-C4). The CBD preparation can be used in combination with other anti-epileptic drugs (AED). The AED can be valproic acid, levetiracetam, clobazam, zonisamide, rufinamide, lacosamide, topiramate, clonazepam, perampanel, brivaracetam, gabapentin, or phenobarbital. The CBD can be isolated from cannabis plant material. The CBD can be present as a synthetic preparation. The CBD preparation can be used at a dose greater than 5 mg/kg/day (e.g. 20, 25, or 50 mg/kg/day). A further aspect of the invention is a method of treating seizures associated with gross chromosomal mutation comprising administering a CBD preparation to a subject.